Biophytis Approves All Resolutions at General Meeting

Biophytis SA, a clinical-stage biotechnology company focused on age-related diseases, successfully passed all resolutions during its Combined General Meeting on June 24, 2024. The meeting achieved a quorum with almost 34% of shareholders present or represented.

Key resolutions included the approval of the financial statements for 2023 and the renewal of directors Stanislas Veillet, Nadine Coulm, and Claude Allary for another three years. Detailed vote results are available on Biophytis' website in the "Investors / General Meetings" section.

This event marks a significant milestone for Biophytis, reinforcing shareholder confidence in its strategic direction and governance.